Table 2. Most frequent adverse events during HeartMate II support as BTT.
| Adverse events | Author (Ref.), study period |
||||
|---|---|---|---|---|---|
| Miller (8), 03/2005-05/2006 | Pagani (9), 03/2005-04/2008 | Starling (10), 04/2008-08/2008 | John (11), 06/2005-06/2010 | Lok (12), 03/2006-12/2011 | |
| Bleeding | |||||
| Re-exploration | 31% | 26% | NR | 16% | NR |
| Gastrointestinal | NR | NR | NR | 17% | 4% |
| CVA | 8% | 20% | |||
| Stroke | 8% | 8% | 6% | NR | NR |
| TIA | 4% | 2% | NR | NR | NR |
| RV failure | 14% | 31% | |||
| Inotropic | 13% | 13% | NR | NR | 27% |
| MCS | 4% | 6% | NR | 4% | 4% |
| Driveline infection | 14% | 14% | 17% | 21% | 14% |
| Pump thrombosis (replacement) | 2% | 1% | NR | 0.98% | 4% |
BTT, bridge-to-transplantation; NR, not reported; CVA, cerebrovascular accidents; TIA, transient ischemic attack; RV, right ventricle; MCS, mechanical circulatory support.